A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

NCT05453903 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

196

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG: Bleximenib
DRUG: Venetoclax (VEN)
DRUG: Azacitidine (AZA)
DRUG: Cytarabine
DRUG: Daunorubicin or Idarubicin

Sponsor

Janssen Research & Development, LLC